Core Insights - The QUEST study, which evaluates the efficacy of traditional Chinese medicine Qiliqiangxin capsules in treating chronic heart failure, has been recognized as one of the top ten research advancements in cardiovascular disease for 2024 [1][4]. Group 1: Study Overview - The QUEST study is the first hard endpoint study in China focusing on traditional Chinese medicine for chronic heart failure, demonstrating a 22% reduction in the risk of major composite endpoint events compared to the control group [4]. - The study also reported a 24% reduction in the risk of heart failure exacerbation leading to rehospitalization and a 17% reduction in cardiovascular mortality, indicating the treatment's safety and good tolerability [4]. Group 2: Subgroup Analyses - Subgroup analyses revealed that Qiliqiangxin capsules have minimal impact on blood pressure and provide clinical benefits for heart failure with reduced ejection fraction (HFrEF) patients, regardless of baseline systolic blood pressure [5]. - The analysis of NT-ProBNP levels showed that Qiliqiangxin significantly lowers plasma NT-proBNP levels in HFrEF patients, demonstrating consistent tolerability across different baseline NT-proBNP levels [5]. - The analysis regarding left ventricular ejection fraction (LVEF) indicated that the benefits of Qiliqiangxin in reducing cardiovascular events are consistent across various LVEF levels, with more significant absolute benefits observed in patients with low LVEF [6]. Group 3: Implications for Traditional Chinese Medicine - The inclusion of the QUEST study in the top ten advancements highlights the scientific value of traditional Chinese medicine in modern medical research and offers new treatment options for patients with reduced ejection fraction heart failure [6]. - The ongoing promotion and application of the study's findings may lead to significant advancements in cardiovascular disease management in China, showcasing the potential of integrating traditional and modern medicine [6].